MDM2-TP53 Crossregulation: An Underestimated Target to Promote Loss of TP53 Function and Cell Survival

Trends in Cancer
Thierry Soussi, G Kroemer

Abstract

Half of human cancers bear inactivating mutations of the tumor suppressor gene TP53, but the other half do not. In a recent issue of Cancer Cell, Dhar et al. and Zhu et al. reported that, in liver cancer and medulloblastoma, MDM2 is constitutively activated, causing a loss of TP53 function that does not require TP53 mutation. On theoretical grounds, such cancer would be amenable to treatment with MDM2 inhibitors.

Related Concepts

Related Feeds

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

Related Papers

Physical Review Letters
X ZhuM L Cohen
Physical Review Letters
H ZhuD Morineau
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Saroj NiraulaIan F Tannock
© 2022 Meta ULC. All rights reserved